Oncobiologics (ONS) Receiving Somewhat Positive Media Coverage, Study Shows

Media headlines about Oncobiologics (NASDAQ:ONS) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Oncobiologics earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.035017323751 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

A number of equities research analysts have recently issued reports on ONS shares. ValuEngine upgraded Oncobiologics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barclays lowered Oncobiologics from an “overweight” rating to an “equal weight” rating in a research note on Monday, January 29th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $9.00.

Oncobiologics (ONS) traded down $0.03 during mid-day trading on Thursday, hitting $1.14. The stock had a trading volume of 30,584 shares, compared to its average volume of 57,644. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of -0.40. Oncobiologics has a fifty-two week low of $0.78 and a fifty-two week high of $3.77.

In other Oncobiologics news, CEO Pankaj Mohan sold 114,677 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $1.17, for a total transaction of $134,172.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Lawrence A. Kenyon sold 26,165 shares of the firm’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $1.13, for a total value of $29,566.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 284,508 shares of company stock valued at $328,317. Insiders own 33.50% of the company’s stock.

WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/oncobiologics-ons-receiving-somewhat-positive-media-coverage-study-shows.html.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Insider Buying and Selling by Quarter for Oncobiologics (NASDAQ:ONS)

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply